Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development

Immunome, Inc. (NASDAQ:IMNM) is one of the best cancer stocks to invest in now. On February 14, Immunome, Inc. (NASDAQ:IMNM) CEO and Chairman Clay Siegall reiterated heightened focus on building an oncology-focused pipeline centered on cell-surface-targeting agents and small molecules.

Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development

David Smart/Shutterstock.com

The ultimate goal is to develop a targeted oncology platform for small molecules that can overcome resistance and enable bystander activity. The remarks come on the company delivering top-line Phase 3 results for Varegacestat in desmoid tumors. The company is in the process of filing a New Drug Application as it sets its sights on a $1 billion market opportunity, targeting the over 3,000 patients treated annually.

Immunome also plans to submit three additional INDs this year targeting solid tumor programs. The push comes as the company’s radioligand therapy, which delivers radiation directly to tumors, receives FDA clearance. It is poised to start a clinical trial soon.

Immunome, Inc. (NASDAQ:IMNM) is a clinical-stage biotechnology company focused on discovering and developing first-in-class targeted therapies for oncology, primarily using antibody-drug conjugate (ADC) technology. They use a proprietary, memory B cell-based discovery engine to identify novel antibodies that treat cancers.

While we acknowledge the potential of IMNM to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IMNM and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 13 Best Manufacturing Stocks to Invest In Now and 11 AI Stocks That Will Go to the Moon.

Disclosure: None.  Follow Insider Monkey on Google News.